Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Omar Atiq

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address4104 Outpatient Circle
Mail Slot # 623
Little Rock AR 72205
Phone501-526-6990 x8176
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentOtolaryngology, College of Medicine


    Collapse Overview 
    Collapse overview
    Omar Atiq, MD, a Professor of Medicine in the Department of Internal Medicine, in the Division of Hematology Oncology at UAMS in the College of Medicine. He serves as the Director of the Head and Neck Medical Oncology Service and the Bone Marrow Service at the Winthrop P. Rockefeller Cancer Institute. He is the founding director of the Arkansas Cancer Institute in Pine Bluff and is a fellow of the American College of Physicians. Dr. Atiq received his medical degree from the Khyber Medical College, University of Peshawar, Pakistan, and did his residency and chief residency in internal medicine at the Edward Hines Jr. Veterans Administration Hospital and Foster G. McGaw Hospital of the Loyola University in Chicago. Dr. Atiq did his fellowship training in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center in New York and is board certified in medical oncology, hematology and internal medicine. He is serving as governor of the Arkansas Chapter of the American College of Physicians and is past president, speaker of the house and chairman of the board of Arkansas Medical Society (AMS). Dr. Atiq also sits on the Arkansas State Medical Board. He is commissioner emeritus of the Arkansas Tobacco Settlement Commission, where he served as inaugural vice chair, and he has also served on the Pulaski Academy board. Publications


    Collapse Research 
    Collapse research activities and funding
    201404139     (ATIQ, OMAR)Jun 4, 2018
    Pfizer, Inc. - Pass Through: Washington University
    Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN
    Role: Principal Investigator

    CACTUX-201410073     (ATIQ, OMAR)Dec 5, 2016
    Washington University
    AX-CL-HN-PI-004393, entitled “Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients with Incurable HNSCC
    Role: Principal Investigator

    MEDI4736     (ATIQ, OMAR)Jul 30, 2015
    AstraZeneca
    A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Role: Principal Investigator

    RTOG 0920     (ATIQ, OMAR)Jul 9, 2014
    NIH/Nat. Cancer Institute - Pass Through: Radiation Therapy Oncology Group
    RTOG 0920-Coop Agreement
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Crowley R, Atiq O, Hilden D, Cooney TG. Health Care for Our Nation's Veterans: A Policy Paper From the American College of Physicians. Ann Intern Med. 2021 Nov; 174(11):1600-1602. PMID: 34606323.
      View in: PubMed
    2. Crowley R, Atiq O, Hilden D. Financial Profit in Medicine: A Position Paper From the American College of Physicians. Ann Intern Med. 2021 10; 174(10):1447-1449. PMID: 34487452.
      View in: PubMed
    3. Atiq S, Atiq OO, Atiq ZO, Samad S, Atiq O. A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy. Cureus. 2021 Feb 04; 13(2):e13133. PMID: 33728149.
      View in: PubMed
    4. Adkins D, Ley J, Atiq O, Powell S, Spanos WC, Gitau M, Rigden C, Palka K, Liu J, Oppelt P. Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. Oral Oncol. 2021 04; 115:105173. PMID: 33548860.
      View in: PubMed
    5. Serchen J, Doherty R, Atiq O, Hilden D. A Comprehensive Policy Framework to Understand and Address Disparities and Discrimination in Health and Health Care: A Policy Paper From the American College of Physicians. Ann Intern Med. 2021 04; 174(4):529-532. PMID: 33428444.
      View in: PubMed
    6. Atiq O, Atiq SO, Atiq ZO, Patel V, Atiq MO, Atiq OT. Pembrolizumab-Induced Cold Agglutinin Disease. Am J Case Rep. 2020 Sep 05; 21:e924283. PMID: 32887867.
      View in: PubMed
    7. Serchen J, Doherty R, Atiq O, Hilden D. Racism and Health in the United States: A Policy Statement From the American College of Physicians. Ann Intern Med. 2020 10 06; 173(7):556-557. PMID: 32559145.
      View in: PubMed
    8. Wongsurawat T, Nakagawa M, Atiq O, Coleman HN, Jenjaroenpun P, Allred JI, Trammel A, Puengrang P, Ussery DW, Nookaew I. An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients. J Microbiol Methods. 2019 11; 166:105739. PMID: 31626891.
      View in: PubMed
    9. Atiq SO, Atiq OO, Atiq MO, Phillips KC, Jacks BB, Moreno M, Maraboyina S, Atiq OT. The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer. Am J Case Rep. 2018 Oct 18; 19:1241-1244. PMID: 30333474.
      View in: PubMed
    10. Dunn A, Broadfoot BG, Hunt J, Kaley JR, Atiq O, Gutta NB, Wang X, Gardner JM, Shalin SC. Metastatic laryngeal large cell neuroendocrine carcinoma: A rare case of presentation and extreme tumor burden. J Cutan Pathol. 2018 Mar; 45(3):229-233. PMID: 29194700.
      View in: PubMed
    11. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008 May 10; 26(14):2320-6. PMID: 18467723.
      View in: PubMed
    Atiq's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description